TY - JOUR
T1 - Premature or early bilateral oophorectomy
T2 - a 2021 update
AU - Rocca, W. A.
AU - Mielke, M. M.
AU - Gazzuola Rocca, L.
AU - Stewart, E. A.
N1 - Funding Information:
W. A. Rocca and M. M. Mielke are funded by the National Institutes of Health [U54 AG044170], [RF1 AG055151]; L. Gazzuola Rocca and E. A. Stewart do not receive external funding.
Publisher Copyright:
© 2021 International Menopause Society.
PY - 2021
Y1 - 2021
N2 - In this invited review, we discuss some unresolved and controversial issues concerning premature (<40 years) or early (40–45 years) bilateral oophorectomy. First, we clarify the terminology. Second, we summarize the long-term harmful consequences of bilateral oophorectomy. Third, we discuss the restrictive indications for bilateral oophorectomy in premenopausal women to prevent ovarian cancer that are justified by the current scientific evidence. Fourth, we explain the importance of estrogen replacement therapy when bilateral oophorectomy is performed. Hormone replacement therapy is indicated after bilateral oophorectomy until the age of expected natural menopause like in premature or early primary ovarian insufficiency. Fifth, we discuss the relationship between adverse childhood experiences, adverse adult experiences, mental health, gynecologic symptoms and bilateral oophorectomy. The acceptance and popularity of bilateral oophorectomy over several decades, and its persistence even in the absence of supporting scientific evidence, suggest that non-medical factors related to sex, gender, reproduction, cultural beliefs and socioeconomic structure are involved. We discuss some of these non-medical factors and the need for more research in this area.
AB - In this invited review, we discuss some unresolved and controversial issues concerning premature (<40 years) or early (40–45 years) bilateral oophorectomy. First, we clarify the terminology. Second, we summarize the long-term harmful consequences of bilateral oophorectomy. Third, we discuss the restrictive indications for bilateral oophorectomy in premenopausal women to prevent ovarian cancer that are justified by the current scientific evidence. Fourth, we explain the importance of estrogen replacement therapy when bilateral oophorectomy is performed. Hormone replacement therapy is indicated after bilateral oophorectomy until the age of expected natural menopause like in premature or early primary ovarian insufficiency. Fifth, we discuss the relationship between adverse childhood experiences, adverse adult experiences, mental health, gynecologic symptoms and bilateral oophorectomy. The acceptance and popularity of bilateral oophorectomy over several decades, and its persistence even in the absence of supporting scientific evidence, suggest that non-medical factors related to sex, gender, reproduction, cultural beliefs and socioeconomic structure are involved. We discuss some of these non-medical factors and the need for more research in this area.
KW - Bilateral oophorectomy
KW - cancer prevention
KW - early ovarian insufficiency
KW - estrogen replacement therapy
KW - genetic variants
KW - ovarian cancer
KW - premature ovarian insufficiency
UR - http://www.scopus.com/inward/record.url?scp=85102685534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102685534&partnerID=8YFLogxK
U2 - 10.1080/13697137.2021.1893686
DO - 10.1080/13697137.2021.1893686
M3 - Review article
C2 - 33719814
AN - SCOPUS:85102685534
SN - 1369-7137
VL - 24
SP - 466
EP - 473
JO - Climacteric
JF - Climacteric
IS - 5
ER -